Instrumento Inactivo

Otros idiomas KaloBios Pharmaceuticals Inc Nasdaq

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

01/05	Aprobada la audiencia combinada para la declaración de divulgación y el plan de Humanigen, Inc.	CI
05/01	El desarrollador del tratamiento 19, Humanigen, se declara en quiebra según el Capítulo 11	RE

Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc.	01/05
19 treatment developer Humanigen files for Chapter 11 bankruptcy	05/01
Humanigen, Inc. Filed for Bankruptcy	03/01
Xspray Pharma Names Chief Commercial Officer	15/09/23
Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer	14/09/23
Sector Update: Health Care Stocks Steady in Late Afternoon Trading	25/07/23
Sector Update: Health Care Stocks Steady Tuesday Afternoon	25/07/23
Sector Update: Health Care	25/07/23
Humanigen Issues 'Going Concern' Warning; Shares Hit 52-Week Low	25/07/23
Humanigen, Inc. Announces Board Changes	25/07/23
Humanigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Humanigen, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23
HUMANIGEN, INC. : Cantor Fitzgerald passe à neutre sur le dossier	11/01/23
Humanigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Opthea Appoints CFO	25/10/22
Humanigen, Inc. Announces Executive Changes	29/09/22
Humanigen Chief Medical Officer Adrian Kilcoyne Resigns	02/09/22
Humanigen, Inc. Announces Resignation Adrian Kilcoyne as Chief Medical Officer, Effective September 28, 2022	02/09/22
Humanigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22
HUMANIGEN, INC. : Roth Capital Partners n'est plus positif	13/07/22

No hay resultados para esta búsqueda